Nyrada Inc. (ASX:NYR)

Market Cap	128.75M +85.8%
Revenue (ttm)	2.01M -16.1%
Net Income	-6.56M
EPS	-0.03
Shares Out	247.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,797
Open	0.5000
Previous Close	0.4950
Day's Range	0.4950 - 0.5200
52-Week Range	0.2850 - 1.4350
Beta	0.94
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About Nyrada

Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NYR

Financial Performance

In fiscal year 2026, Nyrada's revenue was 2.01 million, a decrease of -16.08% compared to the previous year's 2.40 million. Losses were -6.56 million, 35.3% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error